4Rupp ME, Holley HP, Lutz J, et al. Phase II, randomized, multicenter, double-Blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaceharide immune globulin in treatment of Staphylococcus aureus bacteremia [J]. Antimierob agents Chemother 2007, 51 (12): 4249- 4254.
5Mack D, Rohde H, Harris LG, et al. Biofilm formation in medical device-related infection [ J]. Artif Organs 2006, 29 : 343- 359.
6Maira-Litran T, Kropoc A, Goldmann D, et al. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide [ J]. Vaccine 2004, 22 : 872- 879.
7Heilmann C, Schweitzer O, Gerke C, et al. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis [JJ. Mol Microbiol 1996, 20(5) :1083-1091.
8Maira-Litra n T, Kropec A, Goldmarm D, et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N- Acetyl-β-( 1-6 )-Glucosamine [ J ]. Infect Immun 2005, 73 (10) : 6752- 6762.
9Rohde H, Burandt EC, Siemssen N, et al. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of Staphylococcus epidermidis and Staphylococcus aureus isolated from prosthetic hip and knee joint infections[ J]. Biomaterials 2007, 28:1711-1720.
10Rohde H, Burdelski C, Bartscht K, et al. Induction of Staphylococcus epidermidis biofilm formation via proteolytic processing of the accumulation-associated protein by staphylococcal and host proteases [J]. Mol Microbiol 2005, 55:1883-1895.
